骨和软组织肉瘤的表观遗传靶向治疗前景。

Q2 Medicine Sarcoma Pub Date : 2021-07-26 eCollection Date: 2021-01-01 DOI:10.1155/2021/5575444

Jun Wang, Arielle Elkrief, Wei Guo, Neerav Shukla, Mrinal Gounder, Marc Ladanyi

{"title":"骨和软组织肉瘤的表观遗传靶向治疗前景。","authors":"Jun Wang, Arielle Elkrief, Wei Guo, Neerav Shukla, Mrinal Gounder, Marc Ladanyi","doi":"10.1155/2021/5575444","DOIUrl":null,"url":null,"abstract":"Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"5575444"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328687/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas.\",\"authors\":\"Jun Wang, Arielle Elkrief, Wei Guo, Neerav Shukla, Mrinal Gounder, Marc Ladanyi\",\"doi\":\"10.1155/2021/5575444\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.\",\"PeriodicalId\":21431,\"journal\":{\"name\":\"Sarcoma\",\"volume\":\"2021 \",\"pages\":\"5575444\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328687/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sarcoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/5575444\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/5575444","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

靶向治疗已经彻底改变了癌症治疗。染色质结构的改变和修饰影响了一些(可能是大多数)骨和软组织肉瘤的肿瘤发生。由于表观遗传调控因子在骨和软组织肉瘤的发展中起着重要作用，表观遗传药物为这些侵袭性癌症的合理靶向治疗提供了新的潜在途径。本文综述了表观遗传药物在骨肉瘤和软组织肉瘤中的临床应用，并概述了目前在这一领域评估表观遗传治疗的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas.

Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Sarcoma Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.